Xin Lang Cai Jing·2025-08-26 02:30Core Viewpoint - Tiger Med's stock price has shown fluctuations, with a year-to-date increase of 23.82% and a recent decline over the past 20 days, indicating mixed market sentiment towards the company [1][2]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is based in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1]. - The main business segments include clinical trial services (49.91% of revenue), clinical trial technical services (48.13%), and other services (1.95%) [1]. Financial Performance - For the first quarter of 2025, Tiger Med reported a revenue of 1.564 billion yuan, a year-on-year decrease of 5.79%, and a net profit attributable to shareholders of 165 million yuan, down 29.61% year-on-year [2]. - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3]. Shareholder Structure - As of March 31, 2025, Tiger Med had 53,800 shareholders, an increase of 1.95% from the previous period. The top shareholders include various mutual funds and ETFs, with notable changes in holdings among major institutional investors [3].